Quest sells saliva diagnostics business as it continues streamlining
This article was originally published in Clinica
Executive Summary
Quest Diagnostics has divested its OralDNA Labs salivary diagnostics business to molecular testing firm Access Genetics for an undisclosed fee, as part of its plan to refocus on its core Diagnostic Information Services business. The move comes not long after Quest announced a major overhaul which went into effect on 1 January and will involve trimming three layers of management and 400-600 job cuts by the end of 2013 (www.clinica.co.uk, 15 October 2012). At the time, it reorganised operations into two new business groups: Diagnostic Information Services, which accounts for most of Quest's revenues; and Diagnostic Solutions. The streamlining initiatives appear to have been instigated by CEO Steve Rusckowski, who took up the position in April after leading Philips Healthcare for six years (www.clinica.co.uk, 12 April 2012). Access Genetics "has provided support and expertise for OralDNA-based testing services for dental professionals since 2008", the companies stated. OralDNA's testing services, currently provided from a facility in Brentwood, Tennessee, will now be based out of Access's CLIA and CAP-certified lab in Eden Prairie, Minnesota.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.